Cartesian Therapeutics, Inc. cash flow to debt ratio of -583.31% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cartesian Therapeutics, Inc.'s free cash flow has decreased 142.30% from $-32.77M last year to $-79.39M, signaling decreasing performance

Cartesian Therapeutics, Inc.'s debt to equity ratio is -0.51, signaling that the company spent its equity and risk bankruptcy.

Cartesian Therapeutics, Inc.'s debt to equity ratio is -0.51, signaling that the company spent its equity and risk bankruptcy.

Cartesian Therapeutics, Inc. has a net cash position, so leverage is healthy.

Cartesian Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cartesian Therapeutics, Inc.'s profit margin has decreased (5.14K%) in the last year from -198.97% to -10.42K%, signaling decreasing performance

Cartesian Therapeutics, Inc.'s short-term assets of $129.28M exceed its short-term liabilities of $14.94M

Cartesian Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cartesian Therapeutics, Inc.'s return on equity of 141.41%, is higher than 15.00%, indicating good performance

Cartesian Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cartesian Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Cartesian Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cartesian Therapeutics, Inc. has negative free cash flow, indicating cash burn

Cartesian Therapeutics, Inc.'s yearly earnings has decreased 68.30% since last year from $-77.42M to $-130.30M, signaling decreasing performance

Cartesian Therapeutics, Inc.'s yearly revenue has decreased 92.81% since last year from $38.91M to $2.80M, signaling decreasing performance

ROIC -30.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cartesian Therapeutics, Inc.'s 3-year revenue CAGR of -70.66% is negative, indicating declining revenue over the past 3 years

Cartesian Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Cartesian Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Cartesian Therapeutics, Inc. has insufficient data to evaluate this check.

Cartesian Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cartesian Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cartesian Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cartesian Therapeutics, Inc. is overvalued relative to its fair value price of -0.82 based on Earnings Fair Value model

Cartesian Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cartesian Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Cartesian Therapeutics, Inc. has a price-to-sales ratio of 174.85x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue